
Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Carol A. Ziomek, PhD is vice president for development at GTC Biotherapeutics, Inc.
Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Published: August 1st 2006 | Updated: